Biomimetic zwitterionic micelles for efficient mucus penetration and pulmonary targeting in acute lung injury
Source abstract
Abstract
Nebulized inhalation represents an attractive approach for pulmonary drug delivery due to its non-invasiveness and direct lung targeting capability. However, the effectiveness of conventional inhaled formulations is limited by their inability to simultaneously evade mucociliary clearance and macrophage phagocytosis, leading to suboptimal lung retention and low bioavailability. To address these challenges, a series of ultra-small zwitterionic "camouflage" micelles, Distearoylphosphatidylethanolamine (DSPE)-block-poly (N-methacryloyloxyethyl-N, N-dimethylammonium-α-N-methylcarboxybetaine) (CB) (D-PCBn), were developed to synergize biomimetic targeting with enhanced mucosal penetration. The micelles feature a DSPE-based core structurally modeled after dipalmitoylphosphatidylcholine (DPPC), a key pulmonary surfactant lipid, enabling biomimetic alveolar targeting. Simultaneously, a carboxybetaine-derived corona facilitates robust hydration-mediated surface lubrication for efficient mucus penetration. Among the series, the optimized D-PCB30 variant exhibited superior mucus-permeating capacity, enhanced pulmonary deposition, and high encapsulation efficiency for dexamethasone. In vivo evaluation in a murine model following aerosol administration demonstrated significantly improved lung accumulation, extended residence time, reduced systemic distribution, and enhanced anti-inflammatory efficacy. Transcriptomic analysis further indicated modulation of critical inflammatory pathways and reprogramming of macrophage polarization (M1 to M2 phenotype), corroborating the therapeutic benefits achieved through enhanced barrier penetration. These results demonstrate the potential of D-PCBn micelles as a promising inhalable nanoplatform for targeted treatment of lung diseases. STATEMENT OF SIGNIFICANCE: Delivering therapeutics to injured lungs is hampered by mucus barriers, rapid clearance, and immune sequestration. Here, we describe ultra-small, biomimetic zwitterionic micelles D-PCBMAn (D-PCB30) that combine a DPPC-mimetic DSPE core with a carboxybetaine corona to create a "camouflage-and-lubricate" nanoplatform. D-PCB30 exhibits a low critical micelle concentration (CMC), high drug loading, and stability upon nebulization, enabling deep mucus penetration, reduced macrophage uptake, and sustained pulmonary residence. When loaded with dexamethasone (DEX) and delivered by nebulization, D-PCB30 increases local drug deposition while reducing systemic exposure, resulting in potent attenuation of LPS-driven inflammation, preservation of alveolar architecture, and diminished fibrotic remodeling. Mechanistically, transcriptomic profiling reveals suppression of TLR/MyD88/NF-κB inflammatory circuits and induction of tissue-repair programs, alongside a shift in macrophage phenotype toward resolution. With an encouraging biosafety profile and mitigated steroid side effects, D-PCB30 represents a clinically promising strategy to overcome pulmonary barriers and to deliver targeted, effective therapies for acute inflammatory lung disease.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Inhalation and Respiratory Drug Delivery · Neonatal Respiratory Health Research · Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (46)
Show source-provided references
1. Inhaling medicines: delivering drugs to the body through the lungs10.1038/nrd2153 ↗
2. Inhaled mRNA nanoparticles dual-targeting cancer cells and macrophages in the lung for effective transfection10.1073/pnas.2304966120 ↗
3. Harnessing inhaled nanoparticles to overcome the pulmonary barrier for respiratory disease therapy10.1016/j.addr.2023.115111 ↗
4. Emerging trends in inhaled drug delivery10.1016/j.addr.2020.07.006 ↗
5. Efficient nebulization and pulmonary biodistribution of polymeric nanocarriers in an acute lung injury preclinical model10.1002/smsc.202400066 ↗
6. Intracellularly synthesized artificial exosome treats acute lung injury10.1021/acsnano.4c01900 ↗
7. Biomimetic MOF nanocarrier-mediated synergistic delivery of mitochondria and anti-inflammatory miRNA to alleviate acute lung injury10.1002/advs.202416594 ↗
8. Inhalable and bioactive lipid-nanomedicine based on bergapten for targeted acute lung injury therapy via orchestrating macrophage polarization
9. NRF2 modulation in TRAMP mice: an in vivo model of prostate cancer10.1007/s11033-022-08052-2 ↗
10. Nrf2 Modulation in breast cancer10.3390/biomedicines10102668 ↗
11. Lung epithelial cell membrane-camouflaged ROS-activatable berberine nanoparticles for targeted treatment in acute Lung injury10.2147/IJN.S514611 ↗
12. Prevention of vascular inflammation by nanoparticle targeting of adherent neutrophils10.1038/nnano.2014.17 ↗
13. Acute respiratory distress syndrome10.1016/S0140-6736(16)00578-X ↗
14. CRESim Working Group, model of mucociliary clearance in cystic fibrosis lungs10.1016/j.jtbi.2015.02.023 ↗
15. A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases10.1186/s12951-022-01307-x ↗
16. Different mucins are produced by the surface epithelium and the submucosa in human trachea: identification of MUC5AC as a major mucin from the goblet cells10.1042/bj3180319 ↗
17. Structure and function of the polymeric mucins in airways mucus10.1146/annurev.physiol.70.113006.100702 ↗
18. Chemical modification of drug molecules as strategy to reduce interactions with mucus10.1016/j.addr.2017.09.020 ↗
19. Gemcitabine and antisense-microRNA Co-encapsulated PLGA–PEG polymer nanoparticles for Hepatocellular Carcinoma therapy10.1021/acsami.6b08153 ↗
20. RGD-decorated PLGA nanoparticles improved effectiveness and safety of cisplatin for lung cancer therapy10.1016/j.ijpharm.2023.122587 ↗
21. ROS-responsive and self-tumor curing methionine polymer library based nanoparticles with self-accelerated drug release and hydrophobicity/hydrophilicity switching capability for enhanced cancer therapy
22. Nanomedicine-based therapeutics to combat acute lung injury10.2147/IJN.S300594 ↗
23. Molecular simulation studies of protein interactions with zwitterionic phosphorylcholine self-assembled monolayers in the presence of water10.1021/la8013046 ↗
24. Zwitterionic materials for antifouling membrane surface construction10.1016/j.actbio.2016.03.038 ↗
25. Poly(carboxybetaine) lipids enhance mRNA therapeutics efficacy and reduce their immunogenicity10.1038/s41563-025-02240-8 ↗
26. Long circulating micelles of an amphiphilic random copolymer bearing cell outer membrane phosphorylcholine zwitterions10.1016/j.actbio.2015.01.019 ↗
27. Molecular understanding and design of zwitterionic materials10.1002/adma.201404059 ↗
28. Zwitterionic hydrogels implanted in mice resist the foreign-body reaction10.1038/nbt.2580 ↗
29. Zwitterionic polymer-functionalized lipid nanoparticles for the nebulized delivery of mRNA10.1021/jacs.4c11347 ↗
30. The effect of different lipid components on the in vitro stability and release kinetics of liposome formulations10.1080/10717540490265243 ↗
31. Enhanced endosomal/lysosomal escape by distearoyl phosphoethanolamine-polycarboxybetaine lipid for systemic delivery of siRNA10.1016/j.jconrel.2013.12.007 ↗
32. Superhydrophilic zwitterionic polymers stabilize liposomes10.1021/la302433a ↗
33. Micelles with ultralow critical micelle concentration as carriers for drug delivery10.1038/s41551-018-0234-x ↗
34. Mucus penetrating and cell-binding polyzwitterionic micelles as potent oral nanomedicine for cancer drug delivery10.1002/adma.202109189 ↗
35. Increasing stiffness promotes pulmonary retention of ligand-directed dexamethasone-loaded nanoparticle for enhanced acute lung inflammation therapy
36. Zwitterionic polydopamine modified nanoparticles as an efficient nanoplatform to overcome both the mucus and epithelial barriers10.1016/j.cej.2021.132107 ↗
37. Current developments in drug delivery with thermosensitive liposomes
38. DOX/ICG coencapsulated liposome-coated thermosensitive nanogels for NIR-triggered simultaneous drug release and photothermal effect10.1021/acsbiomaterials.8b00379 ↗
39. PEGylation for enhancing nanoparticle diffusion in mucus10.1016/j.addr.2017.08.010 ↗
40. Protein nanocages that penetrate airway mucus and tumor tissue10.1073/pnas.1705407114 ↗
41. Dual barrier-penetrating inhaled nanoparticles for enhanced idiopathic pulmonary fibrosis therapy
42. Super-hydrophilic zwitterionic poly(carboxybetaine) and amphiphilic non-ionic poly(ethylene glycol) for stealth nanoparticles10.1016/j.nantod.2012.08.001 ↗
43. Zwitterionic micelles efficiently deliver oral insulin without opening tight junctions10.1038/s41565-020-0693-6 ↗
44. Natural pachypodol integrated, lung targeted and inhaled lipid nanomedicine ameliorates acute lung injury via anti-inflammation and repairing lung barrier10.1016/j.jconrel.2024.09.013 ↗
45. Stimulation of transcription in vitro from a liver-specific promoter by human glucocorticoid receptor (hGRalpha)10.1042/bj3240823 ↗
46. Mutation/polymorphism scanning of glucose-6-phosphatase gene promoter in noninsulin-dependent diabetes mellitus patients